MSU
PBMWW icon

Mizuho Securities USA’s Psyence Biomedical Warrant PBMWW Stock Holding History

Mizuho Securities USA’s Portfolio PBMWW Stock Details PBMWW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-89,325
Closed -$4.47K – 628
2024
Q1 		$4.47K Buy
+89,325
New +$5.57K ﹤0.01% 124

Other funds holding PBMWW

CAC
Cowen and Company New York $2.97B AUM 105.25% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return
MI
MMCAP International Grand Cayman, Cayman Islands $1.18B AUM 50.44% 1-Year Est. Return
Calamos Advisors
Calamos Advisors Naperville, Illinois $30.1B AUM 30.03% 1-Year Est. Return
CF
Cantor Fitzgerald New York $9.31B AUM 73.66% 1-Year Est. Return
SCM
Saba Capital Management New York $3.9B AUM 12.9% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $7.69B AUM 15.48% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $1.68B AUM 373.57% 1-Year Est. Return
CSD
Clear Street Derivatives New York $12.4M AUM 1.7% 1-Year Est. Return
CCM
Context Capital Management Lajolla, California $5.15B AUM 1.28% 1-Year Est. Return

Mizuho Securities USA's PBMWW Position: Q2 2024 in Review

Mizuho Securities USA sold out of Psyence Biomedical Warrant (PBMWW) in Q2 2024, closing a stake of 89,325 shares — an estimated $4.47K sold.

Mizuho Securities USA first reported a position in PBMWW in Q1 2024 and held it in 1 quarter. The position peaked at $4.47K in Q1 2024. 28 funds tracked by Wall St. Rank hold PBMWW as of Q2 2024.

  • Mizuho Securities USA reported no remaining Psyence Biomedical Warrant position as of Q2 2024 after selling out during the quarter.
  • Mizuho Securities USA sold 89,325 Psyence Biomedical Warrant shares in Q2 2024, an estimated $4.47K.
  • Mizuho Securities USA first reported a position in Psyence Biomedical Warrant in Q1 2024 and held it in 1 quarter.
  • Mizuho Securities USA's Psyence Biomedical Warrant position peaked at $4.47K in Q1 2024.
  • 28 funds tracked by Wall St. Rank held Psyence Biomedical Warrant as of Q2 2024.

Based on Mizuho Securities USA's 13F filing for Q2 2024, filed 31 Jul 2024.